MarketCap
Facebook
X
Telegram
Kintara Therapeutics Balance Sheet 2025-2009 | KTRA
Brief overview of Kintara Therapeutics's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets rose from $13.5 million to $27.4 million, a gain of +102%, while CAGR was about 19.2%. The balance sheet expanded rapidly.
Funding shifted toward liabilities: they gained +116.8%, compared with +102% for assets.
Equity accounts for 76.5% of assets. Against the initial 78.1%, the capital position looks resilient.
Negative net debt of -$3.1 million means cash holdings are larger than debt obligations.
The cash share moved from 77.8% to 13.2%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$141.2 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
Kintara Therapeutics's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Kintara Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.12 M | -12.5 M | - | - | - | -182 M | -3.72 M | -5.97 M | -6.59 M | -6.16 M | -1.75 M | - | -3.86 M | -1.79 K | -5.7 K | - | - |
Long Term Debt |
304 K | 42.7 K | - | - | - | - | - | - | - | - | - | - | 272 K | - | - | - | - |
Long Term Debt Current |
199 K | 160 K | 20.8 K | - | - | - | - | - | 33.1 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 1.12 K | 28.1 K | 870 K | 1.21 M | - | 4.89 M | - | - | - | - |
Total Current Liabilities |
5.92 M | 5.33 M | 3.6 M | 3.99 M | 2.78 M | - | - | 1.64 M | 1.3 M | 627 K | 853 K | 300 K | 249 K | 1.13 M | - | - | - |
Total Liabilities |
6.42 M | 5.37 M | 5.92 M | 4.15 M | 2.96 M | - | 2.07 M | 1.64 M | 1.33 M | 1.5 M | 2.06 M | - | 5.14 M | 9.98 K | - | - | - |
Retained Earnings |
-141 M | -111 M | -88.5 M | -136 M | -111 M | - | -60.6 M | -52.4 M | -41.1 M | -32.2 M | -23.5 M | - | -15.9 M | -57.6 K | -38.7 K | - | - |
Total Assets |
27.4 M | 20 M | 4.36 M | 15.9 M | 13.5 M | 182 M | 4.04 M | 7.07 M | 7.91 M | 6.36 M | 2.58 M | - | 4.32 M | 1.79 K | 10.7 K | - | - |
Cash and Cash Equivalents |
3.62 M | 12.7 M | 3.67 M | 11.8 M | 10.5 M | 2.39 M | 3.72 M | 5.97 M | 6.59 M | 6.16 M | 1.75 M | 4.76 M | 4.14 M | 17.8 K | 15 K | 24.4 K | - |
Book Value |
20.9 M | 14.6 M | -1.56 M | 11.8 M | 10.6 M | 182 M | 1.97 M | 5.44 M | 6.58 M | 4.86 M | 512 K | - | -818 K | -8.19 K | 10.7 K | - | - |
Total Shareholders Equity |
20.9 M | 14.6 M | -1.56 M | 12.3 M | 10.6 M | 263 K | 1.97 M | 5.44 M | 6.58 M | 4.86 M | -821 K | -901 K | -818 K | -1.33 M | -877 K | -1.52 K | - |
All numbers in USD currency
Quarterly Balance Sheet Kintara Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
250 K | - | - | - | 42.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 265 | 76 | 1.34 K | 76 | 1.34 K | 5.45 K | 4.07 K | 5.45 K | 249 K | 171 K | 590 K | 694 K | 1.02 M | 1.35 M | - | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.51 M | 8.92 M | 15.2 M | 4.78 M | 5.37 M | 2.44 M | - | 1.52 M | 2.05 M | 3.5 M | 3.32 M | 2.95 M | 3.32 M | 3.59 M | 4.15 M | 3.41 M | 3.62 M | 3.18 M | 2.96 M | 2.74 M | 2.9 M | 2.58 M | 2.68 M | 2.68 M | 1.03 M | 1.34 M | 2.07 M | 2.07 M | 1.27 M | 1.08 M | 1.64 M | 1.64 M | 2.23 M | 1.53 M | 1.33 M | 1.33 M | 892 K | 1.07 M | 1.5 M | 1.5 M | 2.07 M | 3.55 M | 3.4 M | 3.4 M | 2.04 M | 3.98 M | 5.91 M | 4.12 M | 5.14 M | 5.7 M | 14.2 M | 5.14 M | 1.51 M | 1.51 M | 1.51 M | 1.51 M | 4.88 K | - | - | - |
Retained Earnings |
-149 M | -134 M | -127 M | -118 M | -111 M | -162 M | - | -158 M | -156 M | -155 M | -145 M | -148 M | -145 M | -141 M | -136 M | -131 M | -126 M | -120 M | -111 M | -104 M | -97.8 M | -92.4 M | -69.7 M | -69.7 M | -63.9 M | -62.2 M | -60.6 M | -60.6 M | -56.3 M | -54.5 M | -52.4 M | -52.4 M | -47 M | -43.8 M | -41.1 M | -41.1 M | -36.3 M | -34.8 M | -32.2 M | -32.2 M | -22.9 M | -20.2 M | -18.6 M | -18.6 M | -16.4 M | -15.8 M | -14.3 M | - | - | - | - | - | - | - | - | -56.6 K | -53.5 K | -42.6 K | -38.7 K | -38.7 K |
Total Assets |
29.7 M | 25.7 M | 34.6 M | 14.6 M | 20 M | 4.14 M | - | 7.45 M | 1.88 M | 1.48 M | 9.92 M | 6.74 M | 9.92 M | 13.2 M | 15.9 M | 12.8 M | 17.7 M | 22.3 M | 13.5 M | 18.9 M | 20.5 M | 23.1 M | 2.94 M | 2.94 M | 6.51 M | 8.36 M | 4.04 M | 4.04 M | 4.04 M | 4.75 M | 7.07 M | 7.07 M | 12.2 M | 14.4 M | 7.91 M | 7.91 M | 3.59 M | 5.05 M | 6.36 M | 6.36 M | 2.18 M | 2.58 M | 2.58 M | - | 4.13 M | 4.5 M | 5 M | 5 M | 4.32 M | 5.39 M | 6.52 M | 4.32 M | 183 K | 183 K | 183 K | 183 K | 805 | 6.84 K | 10.7 K | 10.7 K |
Cash and Cash Equivalents |
6.3 M | 2.7 M | 8.51 M | 6.22 M | 12.7 M | 19.6 M | 12.3 M | 4.46 M | 658 K | 216 K | 4.87 M | 3.04 M | 4.87 M | 7.08 M | 11.8 M | 8.84 M | 14.1 M | 19.3 M | 10.5 M | 15.7 M | 17.2 M | 22.6 M | 2.39 M | 2.39 M | 6.35 M | 8.06 M | 3.72 M | 3.72 M | 3.7 M | 3.88 M | 3.7 M | 3.88 M | 11 M | 13.2 M | 11 M | 13.2 M | 3.42 M | 4.8 M | 3.42 M | 4.8 M | 1.96 M | 2.8 M | 1.96 M | 2.8 M | 3.96 M | 4.32 M | 3.96 M | 4.32 M | 4.14 M | 5.17 M | 6.28 M | 4.14 M | 17.8 K | 17.8 K | 17.8 K | 17.8 K | 15 K | 6.84 K | 805 | 5.7 K |
Book Value |
23.2 M | 16.8 M | 19.4 M | 9.86 M | 14.6 M | 1.7 M | - | 5.92 M | -164 K | -2.03 M | 6.6 M | 3.79 M | 6.6 M | 9.62 M | 11.8 M | 9.39 M | 14.1 M | 19.2 M | 10.6 M | 16.1 M | 17.6 M | 20.6 M | 263 K | 263 K | 5.48 M | 7.02 M | 1.97 M | 1.97 M | 2.77 M | 3.67 M | 5.44 M | 5.44 M | 9.98 M | 12.9 M | 6.58 M | 6.58 M | 2.7 M | 3.97 M | 4.86 M | 4.86 M | 117 K | -971 K | -821 K | -3.4 M | 2.09 M | 521 K | -901 K | 880 K | -818 K | -304 K | -7.71 M | -818 K | -1.33 M | -1.33 M | -1.33 M | -1.33 M | -4.08 K | 6.84 K | 10.7 K | 10.7 K |
Total Shareholders Equity |
23.2 M | 16.8 M | 19.4 M | 9.86 M | 14.6 M | -2.77 M | -6.96 M | -6.07 M | -164 K | -2.03 M | 6.6 M | 3.79 M | 6.6 M | 9.62 M | 11.8 M | 9.39 M | 14.1 M | 19.2 M | 10.6 M | 16.1 M | 17.6 M | 17.6 M | 17.6 M | 20.6 M | 5.48 M | 5.48 M | 5.48 M | 7.02 M | 2.77 M | 3.67 M | 2.77 M | 3.67 M | 9.98 M | 12.9 M | 6.58 M | 6.58 M | 2.7 M | 3.97 M | 4.86 M | 4.86 M | 117 K | -515 K | -821 K | -821 K | 2.09 M | 521 K | -901 K | 880 K | -818 K | -304 K | -12.8 M | -818 K | -1.33 M | -1.33 M | -1.33 M | -1.33 M | -877 K | 6.84 K | -4.08 K | 10.7 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Kintara Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.